ResearcherUniversidad de GranadaActive in the last 2 years
Macarena Perán
Matched on ORCID iD 0000-0001-7562-2347; OpenAlex author ID A5068882061. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 19
2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 5
- Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts. Last author DOI 10.1038/s41598-025-24863-2↗
- Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. Co-author DOI 10.1016/j.semcancer.2024.09.002↗
- Unveiling the microRNA landscape in pancreatic ductal adenocarcinoma patients and cancer cell models. Co-author DOI 10.1186/s12885-024-13007-w↗
- Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. First author DOI 10.1016/j.drup.2022.100864↗
- Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting. Last author DOI 10.1038/s41598-019-47837-7↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Belén Toledo · 3 shared papers, 2024–2025 · strength 0.64
- Paper Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts. DOI 10.1038/s41598-025-24863-2↗
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Paper Unveiling the microRNA landscape in pancreatic ductal adenocarcinoma patients and cancer cell models. DOI 10.1186/s12885-024-13007-w↗
- Elisa Giovannetti · 3 shared papers, 2022–2025 · strength 0.61
- Paper Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts. DOI 10.1038/s41598-025-24863-2↗
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Paper Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic ca… DOI 10.1016/j.drup.2022.100864↗
- Juan Antonio Marchal · 3 shared papers, 2019–2025 · strength 0.55
- Paper Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts. DOI 10.1038/s41598-025-24863-2↗
- Paper Unveiling the microRNA landscape in pancreatic ductal adenocarcinoma patients and cancer cell models. DOI 10.1186/s12885-024-13007-w↗
- Paper Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engraf… DOI 10.1038/s41598-019-47837-7↗
- Pablo Hernández-Camarero · 2 shared papers, 2019–2025 · strength 0.37
- Alessandro Gregori · 2 shared papers, 2022–2024 · strength 0.35
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Paper Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic ca… DOI 10.1016/j.drup.2022.100864↗
- Benoît Immordino · 1 shared paper, 2024 · strength 0.19
- Manoj Amrutkar · 1 shared paper, 2024 · strength 0.19
- Naomi Walsh · 1 shared paper, 2024 · strength 0.19
- Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.19
- Rita Rebelo · 1 shared paper, 2024 · strength 0.19
- Giulia Lencioni · 1 shared paper, 2024 · strength 0.19
- Justo Pastor Castano · 1 shared paper, 2024 · strength 0.19
- Andrea Pisano · 1 shared paper, 2024 · strength 0.18
- Alberto Porcu · 1 shared paper, 2024 · strength 0.18
- Grazia Fenu · 1 shared paper, 2024 · strength 0.18
- Roberto Madeddu · 1 shared paper, 2024 · strength 0.18
- Geng Xu · 1 shared paper, 2022 · strength 0.16
- Mjriam Capula · 1 shared paper, 2022 · strength 0.16
- Dongmei Deng · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.